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Abstract
Background: Recently, hyperbaric oxygen therapy (HBOT) has increased in popularity as a treatment for autism.
Numerous studies document oxidative stress and inflammation in individuals with autism; both of these conditions have
demonstrated improvement with HBOT, along with enhancement of neurological function and cognitive performance.
In this study, children with autism were treated with HBOT at atmospheric pressures and oxygen concentrations in
current use for this condition. Changes in markers of oxidative stress and inflammation were measured. The children
were evaluated to determine clinical effects and safety.
Methods: Eighteen children with autism, ages 3–16 years, underwent 40 hyperbaric sessions of 45 minutes duration each
at either 1.5 atmospheres (atm) and 100% oxygen, or at 1.3 atm and 24% oxygen. Measurements of C-reactive protein
(CRP) and markers of oxidative stress, including plasma oxidized glutathione (GSSG), were assessed by fasting blood
draws collected before and after the 40 treatments. Changes in clinical symptoms, as rated by parents, were also
assessed. The children were closely monitored for potential adverse effects.
Results: At the endpoint of 40 hyperbaric sessions, neither group demonstrated statistically significant changes in mean
plasma GSSG levels, indicating intracellular oxidative stress appears unaffected by either regimen. A trend towards
improvement in mean CRP was present in both groups; the largest improvements were observed in children with initially
higher elevations in CRP. When all 18 children were pooled, a significant improvement in CRP was found (p = 0.021).
Pre- and post-parental observations indicated statistically significant improvements in both groups, including motivation,
speech, and cognitive awareness (p < 0.05). No major adverse events were observed.
Conclusion: In this prospective pilot study of children with autism, HBOT at a maximum pressure of 1.5 atm with up
to 100% oxygen was safe and well tolerated. HBOT did not appreciably worsen oxidative stress and significantly
decreased inflammation as measured by CRP levels. Parental observations support anecdotal accounts of improvement
in several domains of autism. However, since this was an open-label study, definitive statements regarding the efficacy of
HBOT for the treatment of individuals with autism must await results from double-blind, controlled trials.
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Background
Autism is a neurodevelopmental disorder currently affect-
ing as many as 1 out of 150 individuals in the United
States [1]. Autism is characterized by impairments in
social interaction, difficulty with communication, and
restrictive and repetitive behaviors [2]. Autism tradition-
ally is considered a "static" neurological disorder [3] and
improvements in core autistic features are not common
[4,5]. Furthermore, three rigorously performed epidemio-
logical studies demonstrate that the prevalence of autism
has increased in recent years [6-8]. These facts might
explain why parents of children with autism are more
likely to seek alternative and off-label medical therapies
than parents of children in the general population [9].
One off-label therapy that has recently increased in popu-
larity as a treatment for autism is hyperbaric oxygen ther-
apy (HBOT) [10,11]. Traditionally, HBOT involves
inhaling up to 100% oxygen at a pressure greater than one
atmosphere (atm) in a pressurized chamber [12]. Most
typical indications for HBOT involve the use of hyperbaric
pressures above 2.0 atm. Higher atmospheric pressures
are generally required to treat conditions such as carbon
monoxide poisoning and to improve wound healing
[12,13].
In some studies, the use of oxygen appears to enhance
neurological function. For instance, in a double-blind,
placebo-controlled, cross-over study, oxygen administra-
tion in healthy young adults, when compared to room air,
was demonstrated to enhance cognitive performance,
including improved performance on attention, reaction
times, and word recall [14]. Additionally, in elderly
patients, HBOT at 2.5 atm and 100% oxygen, when com-
pared to a control group, improved cognitive function,
including memory [15]. Because of these outcomes, some
investigators have used HBOT to treat certain neurological
disorders, including chronic and traumatic brain injury
[16-22], as well as fetal alcohol syndrome [23], and clini-
cal improvements in these patients have been observed.
Furthermore, in a recent rat model of traumatic brain
injury, treatment with HBOT at 1.5 atm and 100% oxy-
gen, when compared to a sham-treated normobaric air
group, improved spatial learning and memory [24]. Sev-
eral studies, using HBOT at similar pressures, also demon-
strated clinical improvements in some patients with
cerebral palsy (CP) [25-28] that in some cases was dra-
matic [29]; however, some researchers have questioned
the results of these studies and have called for further con-
trolled trials and a focus on defining the mechanism of
action of HBOT in individuals with CP [30]. It is impor-
tant to note that some of these studies [16,21-24,26] used
lower hyperbaric pressures (1.5 atm or less) than the pres-
sures typically used for most clinical indications [13].
Given this background, some physicians have also
applied similar lower hyperbaric pressures of 1.3 to 1.5
atm in autistic individuals, with oxygen concentrations
ranging from 21% to 100% [10,31].
HBOT for children is generally regarded as safe, even at
pressures of 2.0 atm for 2 hours per day [32]. However, to
our knowledge, the safety of HBOT for autistic children
has not been previously studied; a review of MEDLINE
indicates that there are no prospective studies on the use
of HBOT for autism. Yet, there are anecdotal reports of
clinical improvements in autistic children with hyperbaric
therapy that have been reported by some physicians. For
instance, Heuser et al. treated a four year old child with
autism using hyperbaric therapy at 1.3 atm and 24% oxy-
gen and reported "striking improvement in behavior
including memory and cognitive functions" after only ten
sessions. This child also had marked improvement of cer-
ebral hypoperfusion as measured by pre-hyperbaric and
post-hyperbaric Single Photon Emission Computed Tom-
ography (SPECT) scans [31]. Another case series suggested
that hyperbaric therapy at 1.3 atm led to clinical improve-
ments in six autistic children [10].
Review of the pathophysiology found in some autistic
individuals in conjunction with the mechanisms of action
of HBOT lead to the speculation that HBOT might pro-
duce clinical improvements in autistic individuals [11].
Several studies indicate that some autistic individuals
manifest cerebral hypoperfusion [33-35], neuroinflam-
mation [36-38], and gastrointestinal inflammation
[39,40]. HBOT might ameliorate some of these problems
by improving cerebral hypoperfusion [17,21,31,41], and
by decreasing neuroinflammation and gastrointestinal
inflammation [42-47]. However, no prospective studies
have examined the role of HBOT on inflammation and
cerebral hypoperfusion in autistic individuals.
Furthermore, concerns exist that HBOT might increase
oxidative stress via the production of reactive oxygen spe-
cies [48]. These concerns are especially relevant because
some children with autism express evidence of increased
oxidative stress [49] including lower serum glutathione
levels [50,51], and decreased activities of antioxidant
enzymes including superoxide dismutase (SOD) [52],
glutathione peroxidase [52], catalase [53], and paraoxo-
nase, an enzyme that prevents lipid oxidation and also
inactivates organophosphate toxins in humans [54].
Some autistic children also demonstrate evidence of
increased lipid peroxidation [53,55,56]; this includes
increased malondialdehyde which is a marker of oxidative
stress and lipid peroxidation [57]. A review of the litera-
ture indicates that oxidative stress can occur with HBOT
but appears to be less of a concern at hyperbaric pressures
under 2.0 atm [58]. In fact, with long-term and repeated
administration, HBOT below 2.0 atm can actually
decrease oxidative stress [59-61] by reducing lipid peroxi-BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
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dation [62], and by up-regulating the activity of antioxi-
dant enzymes including SOD [60,63], glutathione
peroxidase [64], catalase [65], and paraoxonase [62,66].
Furthermore, at the pressures examined in this current
study (1.3 to 1.5 atm), a search of the literature failed to
identify any studies indicating that oxidative stress wors-
ened with HBOT.
Alternatively, some evidence suggests that HBOT could
actually alleviate oxidative stress in children with autism.
For example, halving oxygen concentrations in normal
healthy volunteers results in relative hypoxia and actually
increases oxidative stress [67]. There are several studies
that demonstrate evidence of cerebral hypoxia, as meas-
ured by a reduction in brain Bcl-2 and an increase in brain
p53, among some autistic individuals [68-71]. Elevated
p53 is induced by hypoxia [72] and a decrease in Bcl-2 is
associated with increased apoptosis provoked by hypoxia
[73]. Therefore, in theory, improving hypoxic areas in the
autistic brain might decrease oxidative stress. However,
the effects of HBOT on oxidative stress in autistic individ-
uals are unknown. To our knowledge, there have been no
studies performed which examine the role of HBOT on
oxidative stress in autistic children.
This present study examined hyperbaric therapy at the low
and the high ends of the ranges of atmospheric pressures
and oxygen concentrations currently employed in individ-
uals with autism: 1.3 atm and 24% oxygen [31], and 1.5
atm and 100% oxygen. This study had several objectives.
First, since increased oxidative stress is found in some
autistic children, the effects of HBOT on oxidative stress
markers before and after 40 hyperbaric treatments were
measured. Second, evidence of increased inflammation is
found in many autistic individuals. HBOT is also known
to have anti-inflammatory effects; therefore, the impact of
HBOT on an inflammatory marker (C-reactive protein)
was measured. Third, since the efficacy of HBOT in autism
has not been previously evaluated, this current open-label
pilot study (without a placebo-control group) examined
the changes in clinical symptoms, as rated by parents or
caregivers, after treatment with HBOT. Finally, the safety
of HBOT, used at 1.3 and 1.5 atm, was evaluated in autis-
tic children.
Methods
Patients
Eighteen children, 4 girls and 14 boys, ages ranging 3 to
16 years, were assessed for participation and enrolled in
the study. Six children were non-randomly assigned to 1.5
atm and 100% oxygen, and the 12 remaining children
were non-randomly assigned to 1.3 atm and 24% oxygen.
This unequal division of children among the sample
groups occurred due to scheduling constraints and
because one center (EM) only treated the 1.3 atm group (6
children) while the other center (DR) treated both the 1.3
atm (6 children) and the 1.5 atm (6 children) groups. All
participants were diagnosed with autistic disorder from an
independent psychologist, neurologist, psychiatrist, or
developmental pediatrician and met the DSM IV criteria
for autistic disorder [2]. Children with a diagnosis of Per-
vasive Developmental Disorder – Not Otherwise Speci-
fied (PDD-NOS) or Asperger Syndrome were excluded
from this study. Children with a history of seizure disor-
der were also excluded. Written informed consent was
obtained from the parents and, when possible, the child.
The study and protocol were approved by the Liberty
Institutional Review Board. Baseline Childhood Autism
Rating Scale (CARS) scores were obtained to determine
autism severity; degrees of autism were similar in both
groups (see Table 1). During the study period, children
were not allowed to begin any new therapies or stop any
Table 1: Baseline participant characteristics and supplement profiles
1.3 atm group 1.5 atm group Comparison between groups (p-value)
A. Child characteristics
Age Range 3–16 3–16
Mean Age 6.2 ± 4.0 7.7 ± 4.5 NS
Mean initial CARS score 33.8 ± 6.3 34.4 ± 8.0 NS
B. Percentage of children on supplement
Multivitamin 92% 100% NS
Minerals 75% 67% NS
Digestive Enzymes 42% 17% NS
Probiotics 50% 17% NS
Omega-3 fatty acids 92% 100% NS
Methylcobalamin 58% 83% NS
Folinic acid 42% 83% NS
Glutathione 25% 50% NS
NS = not statistically significantBMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
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current therapies, including medications and supple-
ments. The children in this study were recruited from two
practices (DR and EM) in which antioxidant use and treat-
ments to raise glutathione levels are common therapies.
Because of this, many of the children were already taking
supplements before the study began, such as folinic acid
or methylcobalamin (see Table 1). No significant differ-
ences in supplement usage, age, or initial CARS score were
found between the children in the 1.5 atm group as com-
pared to the 1.3 atm group.
Hyperbaric treatment protocol at 1.3 atm and 24% oxygen
Twelve children (11 boys and 1 girl, mean age 6.2 ± 4.0
years, range 3–16 years) were assigned to separately
receive hyperbaric therapy at approximately 1.3 atm and
24% oxygen in a monoplace hyperbaric chamber. Each
child entered the chamber with a parent or other car-
egiver. Compression time to obtain a pressure of 1.3 atm
was approximately 10 minutes. During this time the chil-
dren equilibrated their middle ears by swallowing liquid,
eating, or yawning. Oxygen at 10 liters per minute from an
oxygen concentrator was mixed with room air and
pumped into the chamber. This resulted in a final cham-
ber oxygen concentration of approximately 24% as meas-
ured by an oxygen monitor. The child was monitored
during the entire treatment cycle. After 45 minutes of 24%
oxygen at 1.3 atm, the chamber was decompressed over
approximately 10 minutes. This therapy was given 45
minutes daily for an average of 4.6 times per week over an
average of a 9.0 week period, for a total of 40 treatments
per child.
Hyperbaric treatment protocol at 1.5 atm and 100% 
oxygen
Six children (3 boys and 3 girls, mean age 7.7 ± 4.5 years,
range 3–16 years) were assigned to separately receive
hyperbaric therapy at 1.5 atm and 100% oxygen in a mon-
oplace hyperbaric chamber. Each child entered the cham-
ber with a parent or other caregiver. Compression time to
obtain a pressure of 1.5 atm was approximately 15 min-
utes. During this time, the children equilibrated their
middle ears by swallowing liquid, eating, or yawning.
Each child was fitted with a rubber-neck collar and clear
plastic hood through which 100% oxygen was delivered.
The rubber-neck collar was applied before getting into the
chamber and the plastic hood was attached after a pres-
sure of 1.5 atm was attained. Two hoses, one for oxygen
input and one for oxygen exit, were then attached to the
hood. The oxygen was then turned on and entered the
hood through one hose and exited through the second
hose and was vented to outside the chamber. The cham-
ber was pressurized with room air and the oxygen concen-
tration of the chamber remained below 23% during the
course of the treatment. The child was monitored during
the entire treatment cycle. After 45 minutes of 100% oxy-
gen at 1.5 atm, the oxygen was turned off, the hood was
removed, and the chamber was decompressed over
approximately 10 minutes. This therapy was given 45
minutes daily for an average of 4.7 times per week over an
average of an 8.8 week period, for a total of 40 treatments
per child.
Blood for C-reactive protein and oxidative stress markers
Immediately prior to the first hyperbaric treatment and
within 24 hours of finishing the 40th (last) hyperbaric
treatment, fasting blood specimens for measuring C-reac-
tive protein (CRP) and oxidative stress profiles were
drawn. The oxidative stress profiles were obtained and
analyzed by SJJ and SM in a blinded fashion according to
procedures previously described [50,51]. The CRPs were
sent to LabCorp for analysis. The technicians at LabCorp
were blinded to the fact that any of the submitted samples
were for use in this study, and the same laboratory instru-
mentation and techniques were used to measure the
before and after CRP samples.
Clinical outcome measures
Pre-treatment scores and post-treatment scores were cal-
culated for each child using the Aberrant Behavior Check-
list – Community (ABC-C), Social Responsiveness Scale
(SRS), and the Autism Treatment Evaluation Checklist
(ATEC). To determine outcomes, a parent or other care-
taker filled out each scale prior to treatment, and after 10,
20, 30, and 40 hyperbaric sessions.
The ABC-C is a 58-item questionnaire that assesses com-
munication, reciprocal social interaction, play, and stere-
otyped behaviors [74]. It is used to evaluate the effects of
medications and other therapeutic interventions and is
scored from 0 ("not at all a problem") to 3 ("problem is
severe in degree"). The ABC-C is widely and successfully
used in clinical trials of autistic individuals [75,76]. For
this study, in addition to scores in 5 subsets (irritability,
social withdrawal (also termed lethargy), stereotypy,
hyperactivity, and inappropriate speech), an overall score
was also calculated.
The SRS is a recently validated test of interpersonal behav-
ior, communication, and stereotypical traits in autism
[77]. It consists of five subscales: social awareness, social
cognition, social communication, social motivation, and
autistic mannerisms. The SRS measures the degree of
social impairments in autistic children and is suitable for
assessing treatment outcomes. In this study, a total raw
score was obtained and raw scores were calculated for
each subscale.
The ATEC is a questionnaire that was developed by the
Autism Research Institute to evaluate treatment efficacy in
autistic individuals. It consists of four subscales labeled:BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
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Speech/Language/Communication, Sociability, Sensory/
Cognitive Awareness, and Health/Physical/Behavior. The
scores are weighted according to the response and the cor-
responding subscale. The higher the subscale and total
scores, the more impaired the subject. A split-half reliabil-
ity analysis on 1,358 checklists indicated high internal
consistency among the questions within each subscale
[78]. ATEC is used in some studies as an outcome measure
[79,80]. It is designed to allow parents and physicians to
assess outcomes of certain treatments commonly used in
autistic individuals. In this study, scores were calculated
for the total score and the four separate subscales.
Safety Assessments
In descending order, the most common side effects found
during HBOT are barotrauma (2% incidence), sinus
squeeze, serous otitis, claustrophobia, reversible myopia,
and new onset seizure (which occurs in 1–3 per 10,000
treatments) [12]. Before beginning the study, each child
underwent a physical examination by either DR or EM;
this included close examination of the ears and tympanic
membranes. During each treatment, a parent or caregiver
entered the chamber with each child. Throughout the
treatment, children were monitored closely by the cham-
ber operator for any signs of ear pain, and parents were
instructed on how to recognize ear pain in their child.
One child in the 1.5 atm group could not tolerate the pres-
sure given during the first HBOT session, and the treat-
ment had to be stopped after just several minutes (the
pressure obtained in this session was approximately 1.1
atm). Examination of the child's ears did not demonstrate
any barotrauma. However, the child's typanostomy tubes
had recently fallen out; these were replaced before contin-
uing the trial, and the child was able to finish 40 treat-
ments without further incident. No other adverse events
were found during this study, including barotrauma or
seizures. All children finished 40 hyperbaric treatments.
Data analysis
All data are presented as means ± SDs. The data were pro-
spectively collected and analyzed using SigmaStat soft-
ware. Statistical differences in changes in each scale (ABC-
C, SRS, and ATEC) and changes in CRP and oxidative
stress markers between baseline versus end of 40 hyper-
baric treatments were ascertained using the Student's t test
with significance set at 0.05.
Results
Oxidative stress profiles
Figure 1(a–d) lists the oxidative stress profile findings; the
first column in each graph is the mean value for control
children as described by James et al. [51] and is included
Changes in mean blood values before and after hyperbaric therapy at both 1.3 atm and 1.5 atm Figure 1
Changes in mean blood values before and after hyperbaric therapy at both 1.3 atm and 1.5 atm. The first column in a-d is the 
mean value for control children as described by James et al. [51] and is included as a standard reference (labeled as "control"). 
P-values and blood levels are listed above the bar graphs. a: Changes in mean oxidized glutathione levels. b: Changes in mean 
tGSH/GSSG.c: Changes in mean fGSH/GSSG. d: Changes in mean adenosine levels
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as a standard reference (labeled as "control"). Mean
plasma oxidized glutathione (GSSG) did not significantly
change in either the 1.3 atm group (p = 0.557) or the 1.5
atm group (p = 0.583). Total plasma glutathione (tGSH)
to GSSG ratio (tGSH/GSSG) (p = 0.146 at 1.3 atm; p =
0.072 at 1.5 atm) and free glutathione (fGSH) to GSSG
ratio (fGSH/GSSG) (p = 0.040 at 1.3 atm; p = 0.076 at 1.5
atm) both decreased after HBOT at 1.3 atm and 1.5 atm.
Mean adenosine slightly increased at 1.3 atm (p = 0.588),
and decreased at 1.5 atm (p = 0.078).
CRP profiles
Figure 2 shows the changes in mean CRP in both groups.
In the 1.3 atm group, mean CRP level declined by 89.5%
from 6.1 ± 10.3 mg/L to 0.64 ± 0.87 mg/L (p = 0.123). Of
note, 3 children had a mean starting CRP value of 21.8 ±
9.2 mg/L ("high CRP group"), which declined to 0.2 mg/
L in each child (p = 0.052) after hyperbaric therapy. Anal-
ysis of the remaining 9 children ("low CRP group") dem-
onstrated no significant change in mean CRP values (0.88
mg/L to 0.79 mg/L, p = 0.854). In the 1.5 atm group,
mean CRP declined by 61.4% from 0.7 ± 0.5 mg/L to 0.27
± 0.19 mg/L (p = 0.084). Examination of CRP in all 18
children in the study demonstrated that CRP declined by
88.4% from a mean starting value of 4.3 ± 8.7 mg/L to 0.5
± 0.7 mg/L (p = 0.021).
Clinical Outcomes
1.3 atm group analysis
Table 2 shows improvements in SRS (p = 0.046) and
ATEC (p = 0.007) for the 12 children in the 1.3 atm group.
Evaluation of the ABC-C, SRS, and ATEC subscales (Figure
3a–c) demonstrates significant improvements in SRS
communication (p = 0.035); SRS motivation (p = 0.021);
SRS mannerisms (p = 0.011); ATEC speech/language/
communication (p = 0.033); ATEC sensory/cognitive
awareness (p = 0.026); and ATEC health/physical/behav-
ior (p = 0.012).
1.5 atm group analysis
Table 3 shows improvements in SRS (p = 0.035) and
ATEC (p = 0.020) for the 6 children in the 1.5 atm group.
Examination of the subscales (Figure 4a–c) demonstrates
significant improvements in ABC-C social withdrawal (p
= 0.008); SRS motivation (p = 0.018); ATEC speech/lan-
guage/communication (p = 0.040); and ATEC sensory/
cognitive awareness (p = 0.013).
Discussion
To our knowledge, this study represents the first prospec-
tive study on the use of HBOT for children with autism. In
this study, lower hyperbaric pressures were used than
those traditionally employed (typically pressures of 2.0
atm and above [13]) for the treatment of most clinical
indications. However, significant increases in oxygen
delivery were obtained during this study. The oxygen con-
centration in room air at sea level (1 atm) is about 160
mmHg. The two study sites were located at approximately
500 and 900 feet above sea level (0.97–0.98 atm). There-
fore, the oxygen delivery in the 1.3 atm group was approx-
imately 232 mmHg which is roughly 45% more than
room air conditions. In the 1.5 atm group, the oxygen
delivery was 1142 mmHg, or over 7 times more than
room air conditions. The amount of oxygen delivered in
the 1.3 atm group is similar to the amount used in a pre-
vious study on HBOT in children with CP that utilized 1.3
atm and room air pressure ("hyperbaric air") [26]. In that
study, the authors commented that the amount of oxygen
delivered at 1.3 atm was achievable with the use of "28%
oxygen with a mask, without pressure"; however, this
opinion did not account for the potential clinical effects
of the increased atmospheric pressure delivered, because
even low amounts of increased pressure may lead to sig-
nificant clinical changes [44,81]. Furthermore, the
authors argued that hyperbaric air at 1.3 atm was unlikely
to provide clinical benefit(s) because the mechanism of
action of HBOT in CP is thought to be due to the "penum-
bra phenomenon" and that a clinical effect due to "a pure
pressure effect" did "not correspond to the rationale
behind the hyperbaric oxygen treatment" [26]. Since the
mechanism of action of HBOT in autism may be different
than in CP [11], including decreasing inflammation (as
reviewed in the background section of this paper), it is
entirely possible that clinical benefits may arise from
purely increasing the atmosphere pressure delivered,
because increased pressure delivery without additional
oxygen appears to decrease inflammation (as measured
by an inhibition of interferon-gamma release), and deliv-
ery of oxygen by mask without any increase in pressure
may actually increase inflammation (as measured by an
increase in interferon-gamma release) [44]. Since HBOT
consists of 2 independent variables (pressure and inspired
oxygen concentration), comparison studies are needed in
individuals with autism before determining that the clin-
Changes in mean CRP before and after hyperbaric therapy at  both 1.3 atm and 1.5 atm Figure 2
Changes in mean CRP before and after hyperbaric therapy at 
both 1.3 atm and 1.5 atm. P-values and blood levels are listed 
above the bar graphs.
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ical effects of 1.3 atm and 24% oxygen are similar to those
obtained by delivering oxygen by mask alone without
additional pressure. In addition, further studies are
needed that evaluate not only the clinical effects of hyper-
oxia delivered by HBOT, but also the effects of increased
atmospheric pressure, because each of these effects may
lead to different clinical outcomes depending on the
underlying disease pathophysiology.
A primary goal of this study was to determine the effects
of HBOT on oxidative stress markers in autistic children.
Other objectives were to measure the effects of HBOT on
CRP and changes in clinical symptoms. The final inten-
tion was to examine the safety of HBOT for use in autistic
children. Of note, shorter duration hyperbaric treatment
times (45 minutes) were used than what is traditional (60
minutes). This was due, in part, to scheduling constraints.
Evaluation of the effects of HBOT on oxidative stress 
markers
Recently, James et al. demonstrated that autistic children
had lower levels of plasma reduced (active) GSH and
increased levels of oxidized (inactive) GSH when com-
pared to control children [51]. The mean tGSH/GSSG
ratio in 73 control children was 28.2 ± 7.0 and in 80 autis-
tic children was 14.7 ± 6.2 (p < 0.0001). The mean fGSH/
GSSG ratio was 7.9 ± 3.5 in control children and 4.9 ± 2.2
in the autistic children (p < 0.0001). The mean GSSG in
control children was 0.24 ± 0.1 µmol/L and 0.40 ± 0.2
µmol/L in the autistic children (p < 0.0001) [51]. In a pre-
vious study, these same researchers demonstrated that the
addition of 800 µg folinic acid, 1000 mg of betaine, and
75  µg/kg of injectable methylcobalamin raised tGSH/
GSSG in 8 autistic children from 7.5 ± 2.3 to 28.7 ± 7.1 (p
= 0.002) and lowered GSSG from 0.59 ± 0.2 nmol/L to
0.25 ± 0.05 nmol/L (p = 0.008). These 8 children had
some improvements in speech and cognition, and after
these treatments, the levels of tGSH/GSSG and GSSG were
both near the levels found in the control children [50].
In the current study, the mean initial tGSH/GSSG was
28.47 ± 4.59 in the 1.3 atm group and 44.68 ± 14.19 in
the 1.5 atm group (see Figure 1b). These values are close
to or higher than the values found in the control children
as described above and are higher than the values
described in some autistic children [50,51]. These
Table 2: Aggregate mean scores for 12 children at 1.3 atm, 24% oxygen
1.3 atm Mean Score Before HBOT Mean Score After HBOT Percentage Improvement p-value
ABC-C 44.4 ± 22.0 40.2 ± 21.5 9.5 0.458
SRS 104.3 ± 29.8 87.1 ± 22.9 16.5 0.046
ATEC 61.4 ± 20.8 54.6 ± 17.2 11.1 0.007
Changes in clinical scales at 1.3 atm and 24% oxygen Figure 3
Changes in clinical scales at 1.3 atm and 24% oxygen. Declin-
ing scores on each scale indicate clinical improvements. 
Scores are listed above the bar graphs at baseline (0) and 
after every 10 treatments (10, 20,30, and 40). P-values are 
listed above the bar graphs. a:Changes in ABC-C subscales at 
1.3 atm and 24% oxygen. b:Changes in SRS subscales at 1.3 
atm and 24% oxygen. c: Changes in ATEC subscales at 1.3 
atm and 24% oxygen.
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increased values might be due to the therapies imple-
mented to raise glutathione levels, including folinic acid
and methylcobalamin, which many of the children were
taking prior to beginning the study. Examination of the
1.3 atm group demonstrates that 7 out of 12 children were
taking folinic acid, methylcobalamin, or both. In the 1.5
atm group, 5 out of the 6 children were taking folinic acid,
methylcobalamin, or both. Interestingly, analysis of
changes in CRP and oxidative stress markers in the chil-
dren taking these 2 supplements when compared to the
children not taking these 2 supplements demonstrated no
statistically significant difference in changes in CRP,
GSSG, tGSH/GSSG, and fGSH/GSSG (data not shown) at
both 1.3 atm and 1.5 atm. In addition, analysis of score
changes on the ABC-C, SRS, and ATEC showed no statisti-
cally significant difference in the children taking either or
both of these 2 supplements when compared to children
not taking these (data not shown). In other words, chil-
dren already taking folinic acid, methylcobalamin, or
both had similar changes in markers of oxidative stress,
CRP, and clinical outcomes as children not taking these
supplements.
In both the 1.3 atm and 1.5 atm groups, after hyperbaric
treatment, the ratios of tGSH/GSSG and fGSH/GSSG were
both close to the values described by James et al. in con-
trol children (see Figure 1b and 1c) and were still higher
than the ratios found in most autistic children [51]. Most
importantly, from an oxidative stress standpoint, the
GSSG levels in both the 1.3 atm and 1.5 atm groups did
not significantly change with treatment and were very
near to the GSSG levels found in control children (see Fig-
ure 1a). Plasma GSSG is a reliable marker of intracellular
oxidative stress because it is only exported from cells
when intracellular levels exceed the redox capacity. Fur-
thermore, plasma GSSG levels are a better indicator of
intracellular oxidative stress than tGSH and fGSH [82].
Therefore, HBOT at the pressures utilized in this study did
not appreciably worsen intracellular oxidative stress as
measured by changes in plasma GSSG. In addition, there
was a trend to lower adenosine levels in the 1.5 atm group
(p = 0.078). Elevated adenosine has been described in a
subgroup of children with autism and typically leads to
elevated S-adenosylhomocysteine (SAH). This is concern-
ing because SAH inhibits most cellular methyltransferases
[51]. Therefore, lowering adenosine levels could be of
Table 3: Aggregate mean scores for 6 children at 1.5 atm, 100% oxygen
1.5 atm Mean Score Before HBOT Mean Score After HBOT Percentage Improvement p-value
ABC-C 56.3 ± 27.3 43.2 ± 25.9 23.3 0.094
SRS 112.3 ± 30.9 95.0 ± 38.9 15.4 0.035
ATEC 61.2 ± 28.0 52.2 ± 28.0 14.7 0.020
Changes in clinical scales at 1.5 atm and 100% oxygen Figure 4
Changes in clinical scales at 1.5 atm and 100% oxygen. 
Declining scores on each scale indicate clinical improve-
ments. Scoresare listed above the bar graphs at baseline (0) 
and after every 10 treatments (10, 20, 30, and 40). P-values 
are listed above the bar graphs. a: Changes in ABC-C sub-
scales at 1.5 atm and 100% oxygen. b: Changes in SRS sub-
scales at 1.5 atm and 100% oxygen. c: Changes in ATEC 
subscales at 1.5 atm and 100% oxygen.
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clinical significance in a subgroup of autistic children with
elevated adenosine levels.
Even though children in this study had similar changes in
oxidative stress markers, CRP, and clinical outcomes
whether or not they were taking folinic acid and/or meth-
ylcobalamin, therapies to raise glutathione levels in autis-
tic children [50] before initiating HBOT at the pressures
used in this study appear prudent. Furthermore, the use of
antioxidants [83] might be beneficial in patients with con-
ditions of increased oxidative stress before HBOT is con-
templated, especially since antioxidant supplementation
is generally recognized as safe. Several antioxidant supple-
ments are known to attenuate oxidative stress induced by
higher pressure HBOT (above 2.5 atm) including α-lipoic
acid [48], melatonin [84], N-acetylcysteine [85,86], Vita-
min E [87], riboflavin [88], selenium [87,88], and glutath-
ione [89]. Furthermore, in two double-blind studies,
treatment with an antioxidant, when compared to a pla-
cebo, improved behavior in some autistic children
[90,91].
Evaluation of the effects of HBOT on C-reactive protein
Since some autistic children have evidence of neuroin-
flammation [36-38] and gastrointestinal inflammation
[39,40], and since HBOT is known to possess anti-inflam-
matory properties [43,92] and can decrease both neuroin-
flammation [42] and gastrointestinal inflammation
[46,47], changes in a marker of inflammation were quan-
tified during this study. CRP was chosen (see Figure 2)
because it is typically elevated with inflammation [93]
and is readily available. In 3 children from the 1.3 atm
group with a very high initial CRP, large improvements in
mean CRP were found after treatment (p = 0.052). The
remaining 9 children in the 1.3 atm group had a small but
non-significant improvement of 0.09 mg/L. However, the
initial mean CRP in these 9 children was 0.88 mg/L which
left little room for improvement. The 1.5 atm group
showed an improvement in mean CRP of 0.43 mg/L (p =
0.084). However, since the children in the 1.5 atm group
started with low initial CRP levels, dramatic improve-
ments in CRP in these children were not possible. Only
those children with an initial high CRP could experience
dramatic improvements, which is what was found in this
study. Pooling the data for changes in CRP values from all
18 children in this study demonstrated a significant
improvement after hyperbaric therapy (p = 0.021). Fur-
ther evaluation of the effects of hyperbaric therapy on
inflammation and inflammatory markers in autistic chil-
dren, especially at varying pressures and oxygen concen-
trations, is warranted.
Evaluation of the effects of HBOT on clinical outcomes
Another outcome of this study was to prospectively exam-
ine if the use of hyperbaric therapy led to improvements
in clinical symptoms. From our clinical experience with
using HBOT in autistic children, some parents have noted
improvements in their children. In this study, an inven-
tory of clinical symptoms affected by HBOT was created to
help determine if a larger controlled trial was justified,
and to investigate which assessment tools might best be
utilized in designing a larger study.
The measurements of these clinical outcomes did have
some inherent limitations and weaknesses. The use of par-
ent-rated scales and the fact that parents were not blinded
to the type of therapy given to their child might have
introduced some bias. Furthermore, there was no placebo
or control group. Therefore, the improvements found in
this open-label study could be due merely to chance or to
the natural development of the children. In addition, it is
possible that any clinical improvements observed could
have occurred as a result of the increased close interaction
between the child and parent/caregiver, or motivation
and/or enthusiasm that may have developed in the par-
ent/caregiver during the course of the treatments. Because
this was a pilot study, the sample sizes were small which
makes it difficult to make adequate and meaningful com-
parisons between the 2 different pressures and oxygen
concentrations used. Due to these issues, a larger double-
blind, prospective study that includes a control group and
more objective outcome measures is warranted.
However, given these limitations, significant improve-
ments in certain areas were found in both the 1.3 atm and
the 1.5 atm groups. These improvements were seen in
diverse areas including irritability, social withdrawal,
hyperactivity, motivation, speech, and sensory/cognitive
awareness (see Figures 3 and 4). This range of improve-
ments was somewhat unexpected, but might be explained
by the fact that many children with autism have cerebral
hypoperfusion which can often vary in location from
child to child [35] and correlates anatomically [11] with
many core autistic symptoms including repetitive, self-
stimulatory behavior [94], and impairments in language
[95] and social interaction [34]. It is possible that HBOT
might help overcome the effects of cerebral hypoper-
fusion by providing more oxygen to the brain [21,41], and
by causing angiogenesis over time [24,92]. As previously
noted, Heuser et al. showed an improvement in cerebral
hypoperfusion as measured by SPECT scans in an autistic
child after hyperbaric therapy at 1.3 atm [31]. Because
HBOT may improve assorted areas of cerebral hypoper-
fusion, and since these areas may additionally differ in
location from child to child, various clinical outcomes
could occur. Further research into this area, utilizing
HBOT combined with pre- and post-hyperbaric SPECT
scans, might be useful in exploring this hypothesis fur-
ther. A weak trend towards increased inappropriate
speech in the 1.3 atm group (see Figure 3a) was observed;BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
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this finding was not seen in the 1.5 atm group (see Figure
4a). Further study on the effects of HBOT at 1.3 atm on
inappropriate speech is warranted.
Evaluation of the Safety of HBOT in Children with Autism
The use of HBOT for children is generally regarded as safe,
even at pressures of 2.0 atm for 2 hours per day [32]. How-
ever, to our knowledge, the safety of HBOT for autistic
children had not been previously evaluated. Therefore,
throughout each hyperbaric session, the children were
intensively monitored. In addition, a parent or caregiver
accompanied each child into the chamber, which pro-
vided additional monitoring. During this study, no signif-
icant adverse events were seen and the treatments were
well tolerated. These results suggest that the hyperbaric
pressures and oxygen concentrations used in this study are
safe in children with autism.
Conclusion
This prospective open-label pilot study in children with
autism indicates, as measured by changes in plasma
GSSG, that HBOT ranging from 1.3 to 1.5 atm and 24% to
100% oxygen was not significantly associated with
increased intracellular oxidative stress. The use of thera-
pies to raise glutathione levels and lower oxidative stress
before beginning HBOT in individuals with autism
appears prudent. Among children with high initial CRP,
hyperbaric therapy led to a large improvement in CRP lev-
els; this suggests that inflammation in these children
improved with treatment. Improvements in clinical out-
comes as measured by several scales were observed at both
1.3 atm and 1.5 atm. However, because this study was
open-label, conclusions about the efficacy of HBOT as a
treatment for autistic children cannot be drawn at this
time. Definitive statements regarding the efficacy of
HBOT for the treatment of children with autism must
await results from future double-blind, controlled trials.
Finally, HBOT was safely administered to autistic children
in this study, and all participants were able to finish 40
HBOT sessions without any major adverse events.
List of abbreviations used
ABC-C – Aberrant Behavior Checklist-Community
ATEC – Autism Treatment Evaluation Checklist
atm – Atmosphere
CARS – Childhood Autism Rating Scale
CP – Cerebral palsy
CRP – C-reactive protein
fGSH – Free glutathione
GSH – Glutathione
GSSG – Oxidized glutathione
HBOT – Hyperbaric oxygen therapy
NS – not statistically significant
PDD-NOS – Pervasive Developmental Disorder – Not
Otherwise Specified
SAH – S-adenosylhomocysteine
SOD – Superoxide dismutase
SPECT – Single photon emission computed tomography
SRS – Social Responsiveness Scale
tGSH – Total glutathione
Competing interests
DR, LR, and EM received funding and reimbursement
from the International Hyperbarics Association in con-
junction with this study. Both DR and EM treat individu-
als with HBOT in their clinical practices and derive
revenue from HBOT. The remaining authors (SJJ and SM)
declare that they have no competing interests.
Authors' contributions
DR and LR conceived of the study and the study design. SJJ
and SM carried out the oxidative stress marker analysis.
DR, LR, EM oversaw the hyperbaric treatments. DR, SJJ,
LR, and EM contributed to the drafting of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors thank Dr. Jeff Bradstreet, Dr. Paul Harch, Mr. Michael Haynes, 
Dr. Jim Neubrander, Dr. Jon Pangborn, Dr. Lauren Underwood, and Dr. 
Kyle Van Dyke for reviewing this manuscript and offering advice. Our grat-
itude goes to Susan Robinson for data collection and study coordination at 
the Advocates for Children site. We appreciate the work of our HBOT 
technicians: Catherine Adams, Kelly Concklin, Leigh Cooper, and Jordan 
Robinson. We are grateful for the work of Shannon Kenitz of the Interna-
tional Hyperbarics Association (IHA) for an unrestricted grant which 
funded the study, which included use of chambers and funding for all blood 
analysis and hyperbaric technician salaries during the study. The IHA had no 
role in the study design, collection, analysis, interpretation of data, writing 
of the manuscript, or in the decision to submit the manuscript for publica-
tion. We especially thank the parents of the children in our study who pro-
vided multiple pages of observations for analysis.
References
1. CDC: Centers for Disease Control and Prevention. Preva-
lence of autism spectrum disorders – autism and develop-
mental disabilities monitoring network, six cities, United
States. 2000.  MMWR 2007, 56:1-40.BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
Page 11 of 13
(page number not for citation purposes)
2. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders.  4th edition. Washington, DC:
American Psychiatric Press; 1994. 
3. Muhle R, Trentacoste SV, Rapin I: The genetics of autism.  Pediat-
rics 2004, 113(5):e472-486.
4. Charman T, Taylor E, Drew A, Cockerill H, Brown JA, Baird G: Out-
come at 7 years of children diagnosed with autism at age 2:
predictive validity of assessments conducted at 2 and 3 years
of age and pattern of symptom change over time.  J Child Psy-
chol Psychiatry 2005, 46(5):500-513.
5. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A: Autism
from 2 to 9 years of age.  Arch Gen Psychiatry 2006, 63(6):694-701.
6. Baird G, Charman T, Baron-Cohen S, Cox A, Swettenham J, Wheel-
wright S, Drew A: A screening instrument for autism at 18
months of age: a 6-year follow-up study.  J Am Acad Child Adolesc
Psychiatry 2000, 39(6):694-702.
7. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P:
Prevalence of autism in a United States population: the
Brick Township, New Jersey, investigation.  Pediatrics 2001,
108(5):1155-1161.
8. Chakrabarti S, Fombonne E: Pervasive developmental disorders
in preschool children.  JAMA 2001, 285(24):3093-3099.
9. Wong HH, Smith RG: Patterns of complementary and alterna-
tive medical therapy use in children diagnosed with autism
spectrum disorders.  J Autism Dev Disord 2006, 36(7):901-909.
10. Rossignol DA, Rossignol LW: Hyperbaric oxygen therapy may
improve symptoms in autistic children.  Med Hypotheses 2006,
67(2):216-228.
11. Rossignol DA: Hyperbaric oxygen therapy might improve cer-
tain pathophysiological findings in autism.  Med Hypotheses
2007, 68(6):1208-1227.
12. Feldmeier JJ, Chairman and Editor: Hyperbaric oxygen 2003: indi-
cations and results: the hyperbaric oxygen therapy commit-
tee report.  Kensington, MD: Undersea and Hyperbaric Medicine
Society; 2003. 
13. Leach RM, Rees PJ, Wilmshurst P: Hyperbaric oxygen therapy.
BMJ 1998, 317(7166):1140-1143.
14. Moss MC, Scholey AB, Wesnes K: Oxygen administration selec-
tively enhances cognitive performance in healthy young
adults: a placebo-controlled double-blind crossover study.
Psychopharmacology (Berl) 1998, 138(1):27-33.
15. Jacobs EA, Winter PM, Alvis HJ, Small SM: Hyperoxygenation
effect on cognitive functioning in the aged.  N Engl J Med 1969,
281(14):753-757.
16. Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE:
Results of a prospective randomized trial for treatment of
severely brain-injured patients with hyperbaric oxygen.  J
Neurosurg 1992, 76(6):929-934.
17. Golden ZL, Neubauer R, Golden CJ, Greene L, Marsh J, Mleko A:
Improvement in cerebral metabolism in chronic brain injury
after hyperbaric oxygen therapy.  Int J Neurosci 2002,
112(2):119-131.
18. Shi XY, Tang ZQ, Sun D, He XJ: Evaluation of hyperbaric oxygen
treatment of neuropsychiatric disorders following traumatic
brain injury.  Chin Med J (Engl) 2006, 119(23):1978-1982.
19. Golden Z, Golden CJ, Neubauer RA: Improving neuropsycholog-
ical function after chronic brain injury with hyperbaric oxy-
gen.  Disabil Rehabil 2006, 28(22):1379-1386.
20. Hardy P, Johnston KM, De Beaumont L, Montgomery DL, Lecomte
JM, Soucy JP, Bourbonnais D, Lassonde M: Pilot case study of the
therapeutic potential of hyperbaric oxygen therapy on
chronic brain injury.  J Neurol Sci 2007, 253(1–2):94-105.
21. Neubauer RA, James P: Cerebral oxygenation and the recover-
able brain.  Neurol Res 1998, 20(Suppl 1):S33-36.
22. Neubauer RA, Gottlieb SF, Miale A Jr: Identification of hypomet-
abolic areas in the brain using brain imaging and hyperbaric
oxygen.  Clin Nucl Med 1992, 17(6):477-481.
23. Stoller KP: Quantification of neurocognitive changes before,
during, and after hyperbaric oxygen therapy in a case of fetal
alcohol syndrome.  Pediatrics 2005, 116(4):e586-591.
24. Harch PG, Kriedt C, Van Meter KW, Sutherland RJ: Hyperbaric
oxygen therapy improves spatial learning and memory in a
rat model of chronic traumatic brain injury.  Brain Res 2007,
1174:120-129.
25. Montgomery D, Goldberg J, Amar M, Lacroix V, Lecomte J, Lambert
J, Vanasse M, Marois P: Effects of hyperbaric oxygen therapy on
children with spastic diplegic cerebral palsy: a pilot project.
Undersea Hyperb Med 1999, 26(4):235-242.
26. Collet JP, Vanasse M, Marois P, Amar M, Goldberg J, Lambert J, Las-
sonde M, Hardy P, Fortin J, Tremblay SD, Montgomery D, Lacroix J,
Robinson A, Majnemer A: Hyperbaric oxygen for children with
cerebral palsy: a randomised multicentre trial. HBO-CP
Research Group.  Lancet 2001, 357(9256):582-586.
27. Sethi A, Mukherjee A: To see the efficacy of hyperbaric oxygen
therapy in gross motor abilities of cerebral palsy children of
2–5 years, given initially as an adjunct to occupational ther-
apy.  The Indian Journal of Occupational Therapy 2003, 25(1):7-11.
28. Waalkes P, Fitzpatrick DT, Stankus S, Topolski R: Adjunctive HBO
treatment of children with cerebral anoxic injury.  Army Med-
ical Department Journal 2002, April-June:13-21.
29. Marois P, Vanasse M: Hyperbaric oxygen therapy and cerebral
palsy.  Dev Med Child Neurol 2003, 45(9):646-647.
30. Bennett M, Newton H: Hyperbaric oxygen therapy and cere-
bral palsy – where to now?  Undersea Hyperb Med 2007,
34(2):69-74.
31. Heuser G, Heuser SA, Rodelander D, Aguilera O, Uszler M: Treat-
ment of neurologically impaired adults and children with
"mild" hyperbaric oxygenation (1.3 ATM and 24% oxygen).
In Hyperbaric oxygenation for cerebral palsy and the brain-injured child
Edited by: Joiner JT. Flagstaff, Arizona: Best Publications; 2002. 
32. Ashamalla HL, Thom SR, Goldwein JW: Hyperbaric oxygen ther-
apy for the treatment of radiation-induced sequelae in chil-
dren. The University of Pennsylvania experience.  Cancer
1996, 77(11):2407-2412.
33. Zilbovicius M, Boddaert N, Belin P, Poline JB, Remy P, Mangin JF, Thi-
vard L, Barthelemy C, Samson Y: Temporal lobe dysfunction in
childhood autism: a PET study. Positron emission tomogra-
phy.  Am J Psychiatry 2000, 157(12):1988-1993.
34. Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema
T, Sasaki M: Abnormal regional cerebral blood flow in child-
hood autism.  Brain 2000, 123(Pt 9):1838-1844.
35. Boddaert N, Zilbovicius M: Functional neuroimaging and child-
hood autism.  Pediatr Radiol 2002, 32(1):1-7.
36. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:
Neuroglial activation and neuroinflammation in the brain of
patients with autism.  Ann Neurol 2005, 57(1):67-81.
37. Pardo CA, Vargas DL, Zimmerman AW: Immunity, neuroglia and
neuroinflammation in autism.  Int Rev Psychiatry 2005,
17(6):485-495.
38. Laurence JA, Fatemi SH: Glial fibrillary acidic protein is elevated
in superior frontal, parietal and cerebellar cortices of autistic
subjects.  Cerebellum 2005, 4(3):206-210.
39. Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch
SB, Walker-Smith J, Thomson M, Wakefield AJ, O'Leary JJ: Potential
viral pathogenic mechanism for new variant inflammatory
bowel disease.  Mol Pathol 2002, 55(2):84-90.
40. Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA,
Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA,
Murch SH: Colonic CD8 and gamma delta T-cell infiltration
with epithelial damage in children with autism.  J Pediatr 2001,
138(3):366-372.
41. Sheffield PJ, Davis JC: Application of hyperbaric oxygen therapy
in a case of prolonged cerebral hypoxia following rapid
decompression.  Aviat Space Environ Med 1976, 47(7):759-762.
42. Vlodavsky E, Palzur E, Soustiel JF: Hyperbaric oxygen therapy
reduces neuroinflammation and expression of matrix metal-
loproteinase-9 in the rat model of traumatic brain injury.
Neuropathol Appl Neurobiol 2006, 32(1):40-50.
4 3. S u me n G , C i ms i t M ,  Er og l u L :  Hyperbaric oxygen treatment
reduces carrageenan-induced acute inflammation in rats.
Eur J Pharmacol 2001, 431(2):265-268.
44. Granowitz EV, Skulsky EJ, Benson RM, Wright J, Garb JL, Cohen ER,
Smithline EC, Brown RB: Exposure to increased pressure or
hyperbaric oxygen suppresses interferon-gamma secretion
in whole blood cultures of healthy humans.  Undersea Hyperb
Med 2002, 29(3):216-225.
45. Wilson HD, Wilson JR, Fuchs PN: Hyperbaric oxygen treatment
decreases inflammation and mechanical hypersensitivity in
an animal model of inflammatory pain.  Brain Res 2006,
1098(1):126-128.BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
Page 12 of 13
(page number not for citation purposes)
46. Takeshima F, Makiyama K, Doi T: Hyperbaric oxygen as adjunct
therapy for Crohn's intractable enteric ulcer.  Am J Gastroen-
terol 1999, 94(11):3374-3375.
47. Buchman AL, Fife C, Torres C, Smith L, Aristizibal J: Hyperbaric
oxygen therapy for severe ulcerative colitis.  J Clin Gastroenterol
2001, 33(4):337-339.
48. Alleva R, Nasole E, Di Donato F, Borghi B, Neuzil J, Tomasetti M:
alpha-Lipoic acid supplementation inhibits oxidative dam-
age, accelerating chronic wound healing in patients undergo-
ing hyperbaric oxygen therapy.  Biochem Biophys Res Commun
2005, 333(2):404-410.
49. Chauhan A, Chauhan V: Oxidative stress in autism.  Pathophysiol-
ogy 2006, 13(3):171-181.
50. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neu-
brander JA: Metabolic biomarkers of increased oxidative
stress and impaired methylation capacity in children with
autism.  Am J Clin Nutr 2004, 80(6):1611-1617.
51. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH,
Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW: Met-
abolic endophenotype and related genotypes are associated
with oxidative stress in children with autism.  Am J Med Genet
B Neuropsychiatr Genet 2006, 141(8):947-956.
52. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T: Investigation of
antioxidant enzymes in children with autistic disorder.  Pros-
taglandins Leukot Essent Fatty Acids 2002, 67(5):341-343.
53. Zoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, Meram
I: Increased oxidative stress and altered activities of erythro-
cyte free radical scavenging enzymes in autism.  Eur Arch Psy-
chiatry Clin Neurosci 2004, 254(3):143-147.
54. D'Amelio M, Ricci I, Sacco R, Liu X, D'Agruma L, Muscarella LA,
Guarnieri V, Militerni R, Bravaccio C, Elia M, Schneider C, Melmed R,
Trillo S, Pascucci T, Puglisi-Allegra S, Reichelt KL, Macciardi F, Holden
JJ, Persico AM: Paraoxonase gene variants are associated with
autism in North America, but not in Italy: possible regional
specificity in gene-environment interactions.  Mol Psychiatry
2005, 10(11):1006-1016.
55. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wag-
ner GC: Increased excretion of a lipid peroxidation biomar-
ker in autism.  Prostaglandins Leukot Essent Fatty Acids 2005,
73(5):379-384.
56. Yao Y, Walsh WJ, McGinnis WR, Pratico D: Altered vascular phe-
notype in autism: correlation with oxidative stress.  Arch Neu-
rol 2006, 63(8):1161-1164.
57. Chauhan A, Chauhan V, Brown WT, Cohen I: Oxidative stress in
autism: increased lipid peroxidation and reduced serum lev-
els of ceruloplasmin and transferrin – the antioxidant pro-
teins.  Life Sci 2004, 75(21):2539-2549.
58. Wada K, Miyazawa T, Nomura N, Tsuzuki N, Nawashiro H, Shima K:
Preferential conditions for and possible mechanisms of
induction of ischemic tolerance by repeated hyperbaric oxy-
genation in gerbil hippocampus.  Neurosurgery 2001,
49(1):160-166.
59. Yatsuzuka H: [Effects of hyperbaric oxygen therapy on
ischemic brain injury in dogs].  Masui 1991, 40(2):208-223.
60. Ozden TA, Uzun H, Bohloli M, Toklu AS, Paksoy M, Simsek G, Durak
H, Issever H, Ipek T: The effects of hyperbaric oxygen treat-
ment on oxidant and antioxidants levels during liver regen-
eration in rats.  Tohoku J Exp Med 2004, 203(4):253-265.
61. Yasar M, Yildiz S, Mas R, Dundar K, Yildirim A, Korkmaz A, Akay C,
Kaymakcioglu N, Ozisik T, Sen D: The effect of hyperbaric oxy-
gen treatment on oxidative stress in experimental acute
necrotizing pancreatitis.  Physiol Res 2003, 52(1):111-116.
62. Kudchodkar BJ, Wilson J, Lacko A, Dory L: Hyperbaric oxygen
reduces the progression and accelerates the regression of
atherosclerosis in rabbits.  Arterioscler Thromb Vasc Biol 2000,
20(6):1637-1643.
63. Gregorevic P, Lynch GS, Williams DA: Hyperbaric oxygen modu-
lates antioxidant enzyme activity in rat skeletal muscles.  Eur
J Appl Physiol 2001, 86(1):24-27.
64. Gulec B, Yasar M, Yildiz S, Oter S, Akay C, Deveci S, Sen D: Effect
of hyperbaric oxygen on experimental acute distal colitis.
Physiol Res 2004, 53(5):493-499.
65. Nie H, Xiong L, Lao N, Chen S, Xu N, Zhu Z: Hyperbaric oxygen
preconditioning induces tolerance against spinal cord
ischemia by upregulation of antioxidant enzymes in rabbits.
J Cereb Blood Flow Metab 2006, 26(5):666-674.
66. Sharifi M, Fares W, Abdel-Karim I, Koch JM, Sopko J, Adler D: Use-
fulness of hyperbaric oxygen therapy to inhibit restenosis
after percutaneous coronary intervention for acute myocar-
dial infarction or unstable angina pectoris.  Am J Cardiol 2004,
93(12):1533-1535.
67. Magalhaes J, Ascensao A, Viscor G, Soares J, Oliveira J, Marques F,
Duarte J: Oxidative stress in humans during and after 4 hours
of hypoxia at a simulated altitude of 5500 m.  Aviat Space Environ
Med 2004, 75(1):16-22.
68. Fatemi SH, Halt AR, Stary JM, Realmuto GM, Jalali-Mousavi M:
Reduction in anti-apoptotic protein Bcl-2 in autistic cerebel-
lum.  Neuroreport 2001, 12(5):929-933.
69. Fatemi SH, Halt AR: Altered levels of Bcl2 and p53 proteins in
parietal cortex reflect deranged apoptotic regulation in
autism.  Synapse 2001, 42(4):281-284.
70. Fatemi SH, Stary JM, Halt AR, Realmuto GR: Dysregulation of Ree-
lin and Bcl-2 proteins in autistic cerebellum.  J Autism Dev Disord
2001, 31(6):529-535.
71. Araghi-Niknam M, Fatemi SH: Levels of Bcl-2 and P53 are altered
in superior frontal and cerebellar cortices of autistic sub-
jects.  Cell Mol Neurobiol 2003, 23(6):945-952.
72. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ:
Hypoxia induces accumulation of p53 protein, but activation
of a G1-phase checkpoint by low-oxygen conditions is inde-
pendent of p53 status.  Mol Cell Biol 1994, 14(9):6264-6277.
73. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K,
Otsuki Y, Matsuda H, Tsujimoto Y: Induction of apoptosis as well
as necrosis by hypoxia and predominant prevention of apop-
tosis by Bcl-2 and Bcl-XL.  Cancer Res 1996, 56(9):2161-2166.
74. Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behav-
ior checklist: a behavior rating scale for the assessment of
treatment effects.  Am J Ment Defic 1985, 89(5):485-491.
75. Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL,
Cook EH Jr: An open-label trial of escitalopram in pervasive
developmental disorders.  J Am Acad Child Adolesc Psychiatry 2005,
44(4):343-348.
76. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG,
Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D,
Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll
D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello
B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pedi-
atric Psychopharmacology Autism Network: Risperidone in chil-
dren with autism and serious behavioral problems.  N Engl J
Med 2002, 347(5):314-321.
77. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Bro-
phy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W: Validation
of a brief quantitative measure of autistic traits: comparison
of the social responsiveness scale with the autism diagnostic
interview-revised.  J Autism Dev Disord 2003, 33(4):427-433.
78. Edelson SM, Rimland B: Autism Treatment Evaluation Check-
list (ATEC): Reliabilities and Score Distributions.  2000 [http:/
/www.autism.com/ari/atec/atec_report.htm].
79. Lonsdale D, Shamberger RJ, Audhya T: Treatment of autism spec-
trum children with thiamine tetrahydrofurfuryl disulfide: a
pilot study.  Neuro Endocrinol Lett 2002, 23(4):303-308.
80. Jarusiewicz B: Efficacy of neurofeedback for children in the
autism spectrum: a pilot study.  J Neurotherapy 2002, 6(4):39-49.
81. Shiratsuch H, Basson MD: Differential regulation of monocyte/
macrophage cytokine production by pressure.  Am J Surg 2005,
190(5):757-762.
82. Dickinson DA, Forman HJ: Glutathione in defense and signaling:
lessons from a small thiol.  Ann N Y Acad Sci 2002, 973:488-504.
83. Patel V, Chivukula IV, Roy S, Khanna S, He G, Ojha N, Mehrotra A,
Dias LM, Hunt TK, Sen CK: Oxygen: from the benefits of induc-
ing VEGF expression to managing the risk of hyperbaric
stress.  Antioxid Redox Signal 2005, 7(9–10):1377-1387.
84. Pablos MI, Reiter RJ, Chuang JI, Ortiz GG, Guerrero JM, Sewerynek
E, Agapito MT, Melchiorri D, Lawrence R, Deneke SM: Acutely
administered melatonin reduces oxidative damage in lung
and brain induced by hyperbaric oxygen.  J Appl Physiol 1997,
83(2):354-358.
85. Yu SY, Chiu JH, Yang SD, Yu HY, Hsieh CC, Chen PJ, Lui WY, Wu
CW:  Preconditioned hyperbaric oxygenation protects the
liver against ischemia-reperfusion injury in rats.  J Surg Res
2005, 128(1):28-36.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pediatrics 2007, 7:36 http://www.biomedcentral.com/1471-2431/7/36
Page 13 of 13
(page number not for citation purposes)
86. Pelaia P, Rocco M, De Blasi RA, Spadetta G, Alampi D, Araimo FS,
Nicolucci S: [Assessment of lipid peroxidation in hyperbaric
oxygen therapy: protective role of N-acetylcysteine].  Minerva
Anestesiol 1995, 61(4):133-139.
87. Hollis AL, Butcher WI, Davis H, Henderson RA, Stone WL: Struc-
tural alterations in retinal tissues from rats deficient in vita-
min E and selenium and treated with hyperbaric oxygen.  Exp
Eye Res 1992, 54(5):671-684.
88. Boadi WY, Thaire L, Kerem D, Yannai S: Effects of dietary factors
on antioxidant enzymes in rats exposed to hyperbaric oxy-
gen.  Vet Hum Toxicol 1991, 33(2):105-109.
89. Weber CA, Duncan CA, Lyons MJ, Jenkinson SG: Depletion of tis-
sue glutathione with diethyl maleate enhances hyperbaric
oxygen toxicity.  Am J Physiol 1990, 258(6 Pt 1):L308-312.
90. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L: A prelimi-
nary trial of ascorbic acid as supplemental therapy for
autism.  Prog Neuropsychopharmacol Biol Psychiatry 1993,
17(5):765-774.
91. Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K,
Black C, Komen J: Double-blind, placebo-controlled study of L-
carnosine supplementation in children with autistic spec-
trum disorders.  J Child Neurol 2002, 17(11):833-837.
92. Al-Waili NS, Butler GJ: Effects of hyperbaric oxygen on inflam-
matory response to wound and trauma: possible mechanism
of action.  ScientificWorldJournal 2006, 6:425-441.
93. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect
of C-reactive protein on human endothelial cells.  Circulation
2000, 102(18):2165-2168.
94. Starkstein SE, Vazquez S, Vrancic D, Nanclares V, Manes F, Piven J,
Plebst C: SPECT findings in mentally retarded autistic individ-
uals.  J Neuropsychiatry Clin Neurosci 2000, 12(3):370-375.
95. Wilcox J, Tsuang MT, Ledger E, Algeo J, Schnurr T: Brain perfusion
in autism varies with age.  Neuropsychobiology 2002, 46(1):13-16.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2431/7/36/prepub